Team presents promising results from first clinical trial of next-gen antibody in patients with advanced solid tumors
Initial data from the first phase 1 trial of the bispecific antibody FS222 demonstrate that it is a drug with a manageable safety profile and promising antitumour activity, especially in patients with metastatic cutaneous ...
Jun 3, 2024
0
0